Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-75220795 · 1 trial · 1 indication
Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Number of participants with change from baseline in vital signs abnormalities including temperature, heart rate, respiratory rate, and blood pressure (supine) will be reported.
Number of participants with change from baseline in clinical laboratory abnormalities including hematology, chemistry and urinalysis will be reported.
Number of participants with change from baseline in physical examination abnormalities will be reported.
Number of participants with change from baseline in ECG abnormalities will be reported.
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (SAD) | EXPERIMENTAL | Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo. |
| Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| JNJ-75220795 | DRUG | JNJ-75220795 will be administered subcutaneously. |
| Placebo | DRUG | Matching placebo will be administered subcutaneously. |
Inclusion Criteria: * Participants with certain genetic predisposition to non-alcoholic fatty liver disease (NAFLD) determined at screening * Presence of liver steatosis at screening * Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on...
JNJ-75220795 is an investigational small molecule being developed for the treatment of fatty liver disease. It is administered subcutaneously and is currently in Phase 1 clinical development. The drug is being studied in patients with fatty liver disease, a condition characterized by excess fat accumulation in the liver.
The specific molecular target of JNJ-75220795 has not been disclosed. It is a small molecule administered subcutaneously, and its mechanism of action in treating fatty liver disease is under investigation in clinical trials. The drug is being evaluated for its safety, tolerability, and pharmacokinetics in patients with fatty liver disease.
JNJ-75220795 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is in Phase 1 clinical development for the treatment of fatty liver disease.
JNJ-75220795 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is being studied for its safety and tolerability in patients with fatty liver disease.
JNJ-75220795 has one completed Phase 1 clinical trial registered under NCT04844450, titled "A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795." The trial enrolled 55 participants with fatty liver disease in the United States and was a randomized, double-blind, controlled study.
No alternative names for JNJ-75220795 have been reported. The drug is identified solely by its investigational code, JNJ-75220795, in clinical trial registrations and development documentation.